The exosome treatment solution according to claim 6-2, wherein the preservative comprises at least one of sodium azide, Proclin 300, 5-bromo-5-nitro-1,3-dioxane, and Proclin 900;
- preferably, content of the buffer material in the exosome treatment solution is 2-4% by weight;
- preferably, the buffer material comprises trimethylolaminomethane and a phosphate buffer salt;
- preferably, content of the trimethylolaminomethane in the exosome treatment solution is 0.9-2.1% by weight;
- preferably, content of the phosphate buffer salt in the exosome treatment solution is 1.1-1.9% by weight;
- preferably, the phosphate buffer salt comprises at least one of sodium phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate, further preferably a mixture of disodium hydrogen phosphate and sodium dihydrogen phosphate;
- preferably, a weight ratio of disodium hydrogen phosphate to sodium dihydrogen phosphate is 1:0.7-1.1;
- preferably, the disodium hydrogen phosphate comprises disodium hydrogen phosphate dodecahydrate;
- preferably, the sodium dihydrogen phosphate comprises sodium dihydrogen phosphate dihydrate;
- preferably, content of the ionic strength maintaining agent in the exosome treatment solution is 0.6-1.2% by weight;
- preferably, the ionic strength maintaining agent comprises at least one of potassium chloride, sodium chloride, calcium chloride, and magnesium chloride, further preferably sodium chloride;
- preferably, content of the blocking agent in the exosome treatment solution is 0.8-2.2% by weight;
- preferably, the blocking agent comprises at least one of casein and collagen peptide, and BSA, further preferably BSA;
- preferably, content of the surfactant in the exosome treatment solution is 0.05-0.6% by weight;
- preferably, the surfactant comprises a nonionic surfactant;
- further preferably at least one of a nonionic surfactant containing a polyoxyethylene alcohol structure, a fatty acid ester of polyoxyethylene sorbitol anhydride, polyoxyethylene octyl phenyl ether, and N-D-glucose-N-methylalkylamide;
- still further preferably at least one of an alcohol ethoxylate, a polyoxyethylene-polyoxyalkylene block copolymer, Tween-20, Tween-40, Tween-80, Triton X-100, Triton X-114, Triton X-305, Triton X-405, Triton X-705, MEGA 8, and MEGA 10;
- yet still further preferably Tween-20;
- preferably, content of the chelating agent in the exosome treatment solution is 0.03-0.25% by weight;
- preferably, the chelating agent comprises a water-soluble salt of ethylenediamine tetraacetic acid, further preferably disodium ethylenediamine tetraacetate;
- preferably, content of the sugar in the exosome treatment solution is 0.8-2.2% by weight;
- preferably, the sugar comprises trehalose;
- preferably, content of the preservative in the exosome treatment solution is 0.08-0.22% by weight;
- and
- preferably, the preservative comprises sodium azide or Proclin 300.